http://www.siliconbiosystems.com/press-releases/ne
Post# of 148187
(Total Views: 160)
Posted On: 04/01/2019 5:54:26 AM
http://www.siliconbiosystems.com/press-releas...ast-cancer
Bologna, Italy and Huntingdon Valley, Pa., MARCH 26, 2019 -- Menarini Silicon Biosystems, the pioneer of liquid biopsy technology, today announced that significant advances in research using the company’s CELLSEARCH® and DEPArrayTM technologies will be presented at the upcoming annual meeting of the American Association for Cancer Research (AACR).
One presentation will cover research from Northwestern University that used the FDA-cleared CELLSEARCH Circulating Tumor Cell (CTC) Test to conduct CTC testing on metastatic breast cancer (MBC) patients.* The study was co-authored by Massimo Cristofanilli, M.D., F.A.C.P., Associate Director of Translational Research at Robert H. Lurie Cancer Center, Northwestern University. It will report on a significant correlation between high levels of co-expression of CCR5 and HER2 in CTCs. CCR5 has been associated with cancer stem cells and believed to drive metastatic process. The researchers suggest that CCR5 may contribute to more aggressive phenotype by upregulating HER2 expression. It is the first evidence of identifying CCR5 expression in CTCs as a potential new marker for MBC with potential therapeutic implications.
“This is an exciting study, as it provides evidence of CCR5 being a potential therapeutic target for breast cancer,” said Dr. Cristofanilli. “This observation is the basis of an upcoming clinical trial incorporating detection CCR5/CTC expression and in which we will target CCR5 with a specific antibody in the hopes of preventing metastasis and prolong disease control in patients with TNBC.”
Bologna, Italy and Huntingdon Valley, Pa., MARCH 26, 2019 -- Menarini Silicon Biosystems, the pioneer of liquid biopsy technology, today announced that significant advances in research using the company’s CELLSEARCH® and DEPArrayTM technologies will be presented at the upcoming annual meeting of the American Association for Cancer Research (AACR).
One presentation will cover research from Northwestern University that used the FDA-cleared CELLSEARCH Circulating Tumor Cell (CTC) Test to conduct CTC testing on metastatic breast cancer (MBC) patients.* The study was co-authored by Massimo Cristofanilli, M.D., F.A.C.P., Associate Director of Translational Research at Robert H. Lurie Cancer Center, Northwestern University. It will report on a significant correlation between high levels of co-expression of CCR5 and HER2 in CTCs. CCR5 has been associated with cancer stem cells and believed to drive metastatic process. The researchers suggest that CCR5 may contribute to more aggressive phenotype by upregulating HER2 expression. It is the first evidence of identifying CCR5 expression in CTCs as a potential new marker for MBC with potential therapeutic implications.
“This is an exciting study, as it provides evidence of CCR5 being a potential therapeutic target for breast cancer,” said Dr. Cristofanilli. “This observation is the basis of an upcoming clinical trial incorporating detection CCR5/CTC expression and in which we will target CCR5 with a specific antibody in the hopes of preventing metastasis and prolong disease control in patients with TNBC.”
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼